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1581LDL-C–lowering therapy alone (1). Recently, HPS2-
THRIVE (Heart Protection Study 2–Treatment of HDL
to Reduce the Incidence of Vascular Events) likewise
showed no beneﬁt for combination ER niacin/laropiprant
therapy (2,3). However, niacin added to ongoing statin
therapy has been associated with atherosclerotic lesion
regression (4,5). In an early randomized trial, a niacin
monotherapy group experienced fewer events than subjects
receiving placebo (6). Combination drug regimens including
niacin were associated with event reductions in 3 smaller
trials (7–9).
Pharmacological effects of niacin can be separated into
lipoprotein effects thought to be mediated by actions in
the liver (10,11) and nonlipoprotein effects mediated by the
G-protein–coupled receptor 109A (GPR109A) on adipo-
cytes, macrophages, and dermal dendritic cells or by a direct
action on endothelial cells (10,12–15). These varying effects
of niacin lend importance to the present analysis of the
interaction between plasma lipoproteins, niacin treatment,
and atherothrombotic events in the AIM-HIGH trial.
Methods
Study design. As described previously, AIM-HIGH trial
participants had established stable atherosclerotic disease with
high-density lipoprotein cholesterol (HDL-C) levels<40mg/
dl for men and <50 mg/dl for women, high triglyceride (TG;
150 to 400 mg/dl) level, and LDL-C levels <180 mg/dl
(adjusted for LDL-C–lowering treatment) (1). All subjects
initially received simvastatin 40 mg daily, plus ER niacin
at doses increasing weekly from 500 to 2,000 mg per day.
Subjects tolerating at least 1,500 mg of ER niacin daily were
randomized 1:1 to receive ER niacin or matching placebo
tablets. To disguise treatment assignment, placebo tablets
included 50 mg of immediate-release niacin in each 500- or
1,000-mg tablet. In both treatment groups, simvastatin doses
were adjusted and/or ezetimibe 10 mg daily was added to
maintain LDL-C levels within 40 to 80 mg/dl.
Statistical analysis. Lipoprotein values were measured
according to protocol at baseline and at 1, 3, and 6months and
each year after randomization. Baseline lipoprotein tertiles were
constructed across all randomized subjects. Baselinewas deﬁned
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proteins and cardiovascular (CV)
eventswere examined by using the
primary study endpoint, which
was the ﬁrst occurrence of death
from coronary heart disease,
nonfatal myocardial infarction,
ischemic stroke, hospitalization
for acute coronary syndrome, or
symptom-driven coronary or
cerebral revascularization. Time-
to-event analyses examined the
period from randomization to
a primary endpoint event, withdrawal of consent, loss to
follow-up, administrative censoring, or the end of the double-
blind period. Each lipoprotein was standardized according
to the overall baseline SD.
Hazard ratios (HRs) examining the relationship between
standardized baseline lipoprotein tertiles and events were
calculated from Cox proportional hazards models, adjusted
for sex and diabetes. Heterogeneity between baseline
lipoprotein tertiles and events across randomization
assignment was assessed by including lipoprotein-by-
treatment interaction terms. A subgroup analysis of
subjects simultaneously in the highest tertile of baseline
TG and the lowest tertile of baseline HDL-C was speci-
ﬁed a priori.
The relationship between in-trial standardized lipoprotein
values and events was assessed by averaging values from
scheduled visits after randomization and before the ﬁrst
conﬁrmed primary event, study termination, or the date of
last contact. For each lipoprotein separately, within-subject
averages were included in the Cox proportional hazards
models, adjusted for sex and diabetes. Sensitivity analyses
were performed as described in Online Tables 2 and 3.
Heterogeneity of joint effects of HDL-C, LDL-C, and
log(TG) across treatments was assessed by using the likeli-
hood ratio test to compare the reducedmodel, including terms
for randomized treatment assignment, HDL-C, LDL-C,
log(TG), sex, and diabetes, with the full model, including
these terms plus the 3 lipoprotein-by-treatment interactions
(16,17).
Two-sided p values <0.05 were considered signiﬁcant,
without adjustment for multiple testing. SAS version
9.2 (SAS Institute, Inc., Cary, North Carolina) was used for
all analyses.Results
Study population and lipoprotein changes. All random-
ized subjects were evaluated (N ¼ 3,414). Baseline lipo-
protein levels were assessed in patients receiving statin
therapy (n ¼ 3,196 [93.6%]) and those without statin
therapy (n ¼ 218 [6.4%]). These groups were combined for
the present analysis. Lipoprotein changes according to
baseline lipoprotein tertiles are shown in Online Table 1.
Figure 1 Effect of Treatment on CV Events by Baseline Lipoprotein/Lipid Tertiles
Hazard ratios (HR) for the effect of treatment assignment were calculated by using Cox proportional hazards models, including terms for sex and diabetes. *High triglycerides
(TG) and low high-density lipoprotein cholesterol (HDL-C) designates subjects with highest-tertile TG and lowest-tertile HDL-C levels. Placebo (Plac) tablets included 100- to 150-
mg immediate-release niacin. CI ¼ conﬁdence interval; CV ¼ cardiovascular; ERN ¼ extended-release niacin; LLT ¼ low-density lipoprotein cholesterol–lowering therapy; Pts ¼
Patients; TC ¼ total cholesterol.
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lipoprotein tertiles. Figure 1 shows that treatment
assignment did not signiﬁcantly affect the primary endpoint
of the ﬁrst major CV event in any baseline tertile of lipo-
protein or lipoprotein ratio. For the 522 subjects (15.3%)
who simultaneously had baseline TG levels in the highest
tertile (198 mg/dl) and HDL-C levels in the lowest tertile
(<33 mg/dl), a nonsigniﬁcant trend toward reduction of CV
risk was evident in the ER niacin group (HR: 0.74,
p ¼ 0.073). In a smaller group (n ¼ 439 [12.9%]) that met
somewhat stricter criteria of TG levels 200 mg/dl and
HDL-C levels <32 mg/dl, the trend toward reduced events
in the niacin group was stronger (HR: 0.64, p ¼ 0.032).
Relation of CV events to lipoprotein variables. Baseline
and in-trial HDL-C levels were not signiﬁcantly associated
with CV events in either treatment group (Table 1). In-trialLDL-C levels, non–HDL-C levels, and the total cholesterol/
HDL-C ratio signiﬁcantly predicted events only in the
control group (p < 0.001 to p ¼ 0.003).
HRs for lipoprotein effects onCV events were closer to 1.00
in ER niacin–treated subjects compared with control subjects
for every baseline and in-trial variable (Table 1). In particular,
in-trial LDL-C and non–HDL-C levels were associated with
CV events in the control group (HR: 1.39 and 1.31, respec-
tively) but not in the ER niacin group (HR: 1.01 and 0.98,
respectively), and tests for heterogeneity were signiﬁcant.
Sensitivity analyses either conﬁrmed or did not contradict
this conclusion (Online Tables 2 and 3).Multivariable analysis
was performed to determine whether the overall predictive
impact of in-trial lipoprotein variables (including LDL-C,
HDL-C, and log[TG]) differed according to treatment
assignment. This analysis showed that the treatment groups
Table 1 Relationship of Cardiovascular Events to Baseline and In-Trial Lipoprotein Variables
LLT þ Placebo* LLT þ ERN
Interaction p ValueySD Hazard Ratio (95% CI) p Value Hazard Ratio (95% CI) p Value
Baseline
LDL-C, mg/dl 23.0 1.05 0.941.18 0.37 1.02 0.921.14 0.66 0.60
Log(TG), mg/dl 0.34 1.06 0.931.19 0.38 0.98 0.871.10 0.70 0.44
HDL-C, mg/dl 5.6 0.91 0.801.05 0.19 0.96 0.851.08 0.47 0.78
NonHDL-C, mg/dl 27.0 1.09 0.971.22 0.16 1.01 0.901.13 0.89 0.31
TC/HDL-C ratio 0.97 1.13 1.011.27 0.035 1.02 0.921.14 0.68 0.22
TG/HDL-C ratio 0.41 1.08 0.951.23 0.22 1.00 0.891.12 0.94 0.44
In-trial
LDL-C, mg/dl 23.0 1.39 1.161.67 <0.001 1.01 0.831.22 0.96 0.01
Log(TG), mg/dl 0.34 1.06 0.951.19 0.28 0.97 0.871.08 0.56 0.31
HDL-C, mg/dl 5.6 0.95 0.841.07 0.37 0.99 0.911.08 0.79 0.85
NonHDL-C, mg/dl 27.0 1.31 1.131.52 <0.001 0.98 0.831.15 0.78 0.008
TC/HDL-C ratio 0.97 1.20 1.061.35 0.003 1.04 0.891.20 0.64 0.19
TG/HDL-C ratio 0.41 1.08 0.961.21 0.20 0.99 0.891.09 0.77 0.38
*Placebo tablets included 100 to 150 mg of immediate-release niacin. yInteraction p value assesses the heterogeneity of the effect of lipoprotein across treatment groups.
CI ¼ conﬁdence interval; ERN ¼ extended-release niacin; HDL-C ¼ high-density lipoprotein cholesterol; LDL-C ¼ low-density lipoprotein cholesterol; LLT ¼ LDL-C–lowering therapy; TC ¼ total cholesterol;
TG ¼ triglyceride.
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1583differed signiﬁcantly (p¼ 0.025), suggesting that the use ofER
niacin in patients treated with intensive LDL-C–lowering
therapy reduced the overall impact of lipoproteins on CV
events.
Discussion
The primary result of AIM-HIGH was the lack of an effect
on CV events despite a 15% higher HDL-C level in the
group receiving ER niacin compared with the control group
receiving intensive LDL-C–lowering therapy alone. The
present analysis extends the concept of lack of relationship
with HDL-C because HDL-C levels showed no correlation
with events.
We found no baseline group deﬁned by lipoprotein ter-
tiles in which combined therapy was signiﬁcantly better
than control LDL-C–lowering therapy alone. However, a
nonsigniﬁcant trend toward better outcomes with ER niacin
combined therapy appeared in a small group who had
baseline TG levels in the highest tertile with simultaneous
HDL-C levels in the lowest tertile. This trend toward
beneﬁt in a dyslipidemic subgroup has been noted in
randomized trials of ﬁbrates, which (as with niacin) lower
TG and raise HDL-C levels (18).
In the AIM-HIGH control group, in-trial LDL-C, non–
HDL-C, and the total cholesterol/HDL-C ratio signiﬁ-
cantly predicted atherothrombotic events. In contrast, none
of these atherogenic lipoprotein variables predicted athero-
thrombotic events in the group receiving ER niacin. We also
examined the joint impact of in-trial LDL-C, HDL-C, and
TGs on events, ﬁnding a signiﬁcant difference between the
control group and the ER niacin combined therapy group.
The loss of the relation of in-trial atherogenic lipoproteins
to CV events in ER niacin–treated patients suggests that
niacin may affect the relationship between lipoproteins and
events. This altered relationship implies: 1) niacin-inducedcompositional changes in lipoproteins that make them
neutral with regard to atherothrombosis; 2) an inﬂuence of
niacin on CV events independent of lipoproteins; or 3) both.
We consider the ﬁrst option to be unlikely as a sole expla-
nation and favor the idea that nonlipoprotein effects of
niacin may inﬂuence atherothrombotic events, obscuring the
effects of lipoproteins and leading to HRs close to unity in
the ER niacin combined therapy group.
Recent results from HPS2-THRIVE highlighted the
potential for clinical harm from niacin related to a variety of
off-target (nonlipoprotein) adverse events (2,3). The present
analysis ﬁts with the hypothesis of clinically important
nonlipoprotein effects and extends their potential impact
to the primary outcome variable of CV events.
A well-recognized nonlipoprotein action of niacin is
GPR109A-dependent inhibition of adipocyte TG lipolysis.
Plasma nonesteriﬁed fatty acid levels rapidly fall >60%, then
rebound and overshoot after 1 to 2 h (10,12). This metabolic
perturbation repeated every night could promote CV events via
impairedmyocardial fuel supply, subsequent excess in fatty acid
anion concentrations, and/or a counter-regulatory hormone
response, including catecholamines (19,20). Myocardial ener-
getics are known to shift from fatty acid to glucose oxidation
after niacin administration to fasting humans (12).
Niacin was administered at mealtimes before the intro-
duction of ER niacin in the late 1990s. Mealtime dosing
may avert the metabolic perturbation just described, because
food absorption supports myocardial fuel supply, and
epinephrine is speciﬁcally suppressed (21). The AIM-
HIGH trial was designed largely on the basis of previous
niacin trials with mealtime dosing (6–9). However, in
both the AIM-HIGH and the HPS2-THRIVE trials,
niacin administration shifted to bedtime, potentially
magnifying the consequences of adipocyte lipolysis inhibi-
tion. This nonlipoprotein action of niacin needs further
study in the fasting and post-prandial states.
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matory responses in endothelial cells and macrophages,
and increased cholesterol efﬂux in macrophages (13–15).
Niacin inhibited atherogenesis in wild-type, but not
GPR109A-negative, mice, and the effect was transferable
with GPR109A-competent bone marrow cells (13). In
contrast to adipocyte lipolysis inhibition, these cellular
effects seem generally beneﬁcial. The net effect of multiple
nonlipoprotein actions of niacin, together with the relatively
small 15% HDL-C increase seen in the AIM-HIGH trial,
could bring about a balance of harm and beneﬁt leading to
no overall change in CV events. This hypothesis brings
together diverse clinical and basic results regarding niacin
and is testable at multiple levels.
Study limitations. The present study has limitations as
a secondary analysis, and results should be considered
hypothesis-raising rather than conclusive. The identiﬁcation
of an apparent beneﬁt in a small dyslipidemic subgroup is
subject to error due to multiplicity. Further insights may be
gained by considering apolipoproteins, lipoprotein(a), and
HDL and LDL particle concentrations, which are being
analyzed and presented separately (22).
Conclusions
This analysis reinforces a diminished role for niacin-induced
HDL-C increases in the prevention of atherothrombotic
events. Baseline lipoprotein tertiles did not predict differential
beneﬁt or harm with ER niacin added to aggressive LDL-C–
lowering therapy, but a small subgroup of subjects with
baseline dyslipidemia showed possible beneﬁt. Atherogenic
lipoproteins correlated positively with CV events in the
control group but not in the ER niacin–treated group. This
observation raises the possibility that nonlipoprotein effects of
niacin might have inﬂuenced CV events in AIM-HIGH.
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